Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Eli Lilly continues to benefit from strong demand for its diabetes and weight-loss therapies, which have transformed the company’s growth profile and generated substantial cash flow. Lilly is uniquely...
— Andrew D.W. Hill
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Eli Lilly & Co.
Eli Lilly and Company ($LLY) is a global pharmaceutical leader specializing in treatments for diabetes, obesity, oncology, and immunology, representing the Fund's largest portfolio holding at 14.3% of net assets. The manager maintains...
The company remains a premier growth compounder in the highly underserved global diabetes and obesity therapeutic markets. While the market...
Eli Lilly is the eleventh largest holding. Global branded pharmaceutical...
More institutional theses from Andrew Hill Investment Advisors, Inc.
Nvidia is the preeminent designer of graphic processing units (GPUs) and integrated accelerated computing platforms that serve as the foundational computing hardware for modern artificial intelligence applications. The manager maintains...
Automatic Data Processing is a premier global provider of cloud-based human capital management, payroll processing, tax administration, and benefits administration software. The manager maintains...
Apple designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and an expanding suite of software and digital services. The manager maintains...